Highlight time: top ten investment and financing events in domestic pharmaceutical industry in 2018

Financing in the capital market is always a hot topic, especially in the pharmaceutical capital market In 2018, with the change of regulatory policies and market environment and the coming of capital winter, some entrepreneurial projects fell into the problem of financing difficulties Compared with the previous crazy investment and valuation, the market gradually returned to "calm" On the other hand, capital still maintains a high degree of activity in the pharmaceutical industry, and many medical and health enterprises get sound development through capital assistance Sina medicine has noted that many segments of drug innovation, biotechnology, artificial intelligence, gene sequencing, medical services, Internet plus and other segments have been favored by the capital market The following is a list of ten major investment and financing news of the domestic pharmaceutical industry in 2018 by Sina pharmaceutical: Ping An medical insurance technology obtained US $1.15 billion a round of financing on February 2, and Ping An medical insurance technology, a comprehensive medical insurance and commercial insurance management service provider, completed the first financing of US $1.15 billion, mainly by overseas investors such as Softbank vision fund Micro comment: Ping An medical insurance technology has become the youngest Unicorn enterprise in the field of big health with a valuation of US $8.8 billion On July 12, Sinopharm announced that it signed an asset purchase agreement with the controlling shareholder Sinopharm group on July 11 to acquire 60% of the equity of the target company, China Science Equipment Co., Ltd., for a consideration of RMB 5.1 billion Micro comment: China's medical device industry is in a period of rapid development opportunities This acquisition will help further expand the competitiveness of Sinopharm holdings in the field of medical devices On May 9, the internet medical enterprise micro medical group announced that it had completed the pre IPO round financing of $500 million After the completion of this round of financing, the micro medical group's valuation was $5.5 billion Micro comment: This is the largest pre IPO Financing completed by China's medical and health technology industry so far With the continuous support of capital and the deep expansion of business, the listing of micro medicine has more chips, which is worth looking forward to Fuhong Hanlin has obtained US $190 million and US $157 million respectively in financing since 2018 Fuhong Hanlin has conducted two rounds of financing In January, Fuhong Hanlin raised US $190 million, with a post investment valuation of about 10 billion yuan In July, the financing was about $157 million, and the post investment valuation was about 20 billion yuan The valuation doubled in half a year Micro comment: in the capital market, Fu Hong and Han Lin are lucky Backed by Fosun tree, a number of R & D has progressed smoothly, with frequent financing and multiple increase in valuation On May 24, it was announced that brii Biosciences was officially established and completed US $260 million financing This round of financing is led by arch venture partners, Tonghe Yucheng capital, Boyu capital, Yunfeng fund, Sequoia Capital and LanChi capital Micro review: China has a huge demand for the prevention, treatment and cure of major infectious diseases It is not only a business opportunity, but also an opportunity to significantly improve public health to help the development of public health system through advanced technology and data On May 9, cornerstone Pharmaceutical Co., Ltd announced the completion of round B financing of USD 260 million (about RMB 1.65 billion), becoming the largest single financing in round B in China's biomedical field so far Micro comment: it has obtained about 2.6 billion yuan of financing in the past two years, which shows that the recognition and support of overseas and domestic investment institutions for China's new and innovative pharmaceutical enterprises are more conducive to the sustained development of cancer immunotherapy in cornerstone pharmaceutical industry On June 30, Tianjing biology announced that it had completed the round C financing of 220 million US dollars The financing is led by Hony investment, with participation of Hillhouse capital, Hopu investment, CDH investment, Huiqiao capital and EDBI based in Singapore The existing investors, Kangqiao capital and tisley capital, continue to follow the investment Micro review: Tianjing biology has obtained one of the largest round C financing in the field of innovative drugs in China so far, demonstrating its comprehensive strength and development prospects in the field of global innovative antibody drug research and development On November 27, yaomingcode obtained a round C financing of 200 million US dollars, which was invested by Irish strategic investment fund, Temasek, Yunfeng fund, Sequoia Capital China fund and private investors This is a new round of financing after yaomingcode completed the round B financing of 240 million US dollars in September 2017 Micro review: through the data strategy, yaomingcode further expands the scale and capability of its global leading genomics platform, accelerates the drive of drug discovery, provides precision medical solutions, and benefits patients all over the world Cinda bio obtained 150 million US dollars e-round financing, and IPO raised 3.155 billion Hong Kong dollars On April 27, Cinda bio announced to complete 150 million US dollars e-round financing Capital Group private markets, one of the largest investment organizations in the world, led the financing with 90 million US dollars It was listed on the main board of the Hong Kong Stock Exchange on October 31 and obtained about HK $3.155 billion in IPO Micro review: the macro environment and innovation at home and abroad make biotechnology in a favorable position of continuous value creation Hong Kong stock allows unprofitable biotechnology companies to be listed, creating a win-win opportunity for investors and biopharmaceutical companies On June 22, Yifeng pharmacy announced that the company plans to acquire 86.31% shares of Shijiazhuang Xinxing pharmacy chain Co., Ltd by issuing shares and paying cash, with a transaction price of about 1.38 billion yuan After the completion of the transaction, the equity of Yifeng pharmacy in the emerging pharmacy will increase to 91%, which is in an absolute holding position It took two months for the chain drugstore industry to finish its first merger and acquisition Micro comments: the retail pharmacy industry is experiencing a capital feast The capital, represented by the listed chain leaders, pharmaceutical industry enterprises, industrial capital and cross-border capital, is devouring the retail pharmacy The retail pharmacy has become the "hot cake" of capital Note: with reference to relevant investment and financing data of sina pharmaceutical, Chuangye bang, Qingke, etc., this paper is selected for financing behavior of unlisted enterprises with consideration of hot areas If there is any omission, please understand!